Trial Outcomes & Findings for Characterizing Methamphetamine Withdrawal in Recently Abstinent Methamphetamine Users: A Pilot Study (NCT NCT00653263)

NCT ID: NCT00653263

Last Updated: 2021-06-28

Results Overview

Methamphetamine Selective Severity Assessment (MSSA) is an 18 item questionnaire assessing withdrawal symptoms with each question measured on a scale from 0(best score)-7(worst score) for a range in scores from 0(best score)-126(worst score). Higher scores indicate more severe withdrawal symptoms.

Recruitment status

COMPLETED

Target enrollment

8 participants

Primary outcome timeframe

Baseline through week 4

Results posted on

2021-06-28

Participant Flow

A total of 13 participants were recruited for enrollment in study entry.

A total of 5 participants did not meet study criteria and did not enter the study proper, leaving a total of 8 eligible subjects.

Participant milestones

Participant milestones
Measure
Methamphetamine Dependent
Methamphetamine dependent participants admitted to Recovery Centers of Arkansas
Overall Study
STARTED
8
Overall Study
COMPLETED
6
Overall Study
NOT COMPLETED
2

Reasons for withdrawal

Reasons for withdrawal
Measure
Methamphetamine Dependent
Methamphetamine dependent participants admitted to Recovery Centers of Arkansas
Overall Study
Withdrawal by Subject
1
Overall Study
Physician Decision
1

Baseline Characteristics

Characterizing Methamphetamine Withdrawal in Recently Abstinent Methamphetamine Users: A Pilot Study

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Methamphetamine Dependent
n=8 Participants
Methamphetamine dependent participants admitted to Recovery Centers of Arkansas
Age, Categorical
<=18 years
0 Participants
n=99 Participants
Age, Categorical
Between 18 and 65 years
8 Participants
n=99 Participants
Age, Categorical
>=65 years
0 Participants
n=99 Participants
Age, Continuous
32.67 years
STANDARD_DEVIATION 5.8 • n=99 Participants
Sex: Female, Male
Female
5 Participants
n=99 Participants
Sex: Female, Male
Male
3 Participants
n=99 Participants
Region of Enrollment
United States
8 participants
n=99 Participants

PRIMARY outcome

Timeframe: Baseline through week 4

Methamphetamine Selective Severity Assessment (MSSA) is an 18 item questionnaire assessing withdrawal symptoms with each question measured on a scale from 0(best score)-7(worst score) for a range in scores from 0(best score)-126(worst score). Higher scores indicate more severe withdrawal symptoms.

Outcome measures

Outcome measures
Measure
Methamphetamine Dependent
n=6 Participants
Methamphetamine dependent participants admitted to Recovery Centers of Arkansas
Methamphetamine Selective Severity Assessment (MSSA)
48.2 "units on a scale"
Standard Deviation 26.8

PRIMARY outcome

Timeframe: Baseline through week 4

The Methamphetamine Withdrawal Assessment (MAWA) is a 13 item questionnaire which measures symptoms of methamphetamine withdrawal on a scale from 0(best score)-4(worst score). The total score ranges from 0(best score)-52(worst score).

Outcome measures

Outcome measures
Measure
Methamphetamine Dependent
n=6 Participants
Methamphetamine dependent participants admitted to Recovery Centers of Arkansas
Methamphetamine Withdrawal Assessment (MAWA)
20.3 "Units on a scale"
Standard Deviation 12.5

SECONDARY outcome

Timeframe: 4 weeks

Hamilton Depression rating scale (HAM-D)is a scale that covers 21 symptoms with a total score of 0(best score)-62 (worst score) and a cutoff for moderate depression of 15 or above.

Outcome measures

Outcome measures
Measure
Methamphetamine Dependent
n=6 Participants
Methamphetamine dependent participants admitted to Recovery Centers of Arkansas
Hamilton Depression Rating Scale (HAM-D) Rating Score
18.5 "Units on a scale"
Standard Deviation 13.4

Adverse Events

Methamphetamine Dependent

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Michael J Mancino

UArkansas

Phone: 501-526-8442

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place